Cost effectiveness analysis of ceftriaxone and levofloxacin for therapy of urinary tract infection at Soebandi public hospital
DOI:
https://doi.org/10.46542/pe.2023.232.98102Keywords:
Ceftriaxone, Levofloxacin, Pharmacoeconomics, Urinary Tract InfectionsAbstract
Background: An ideal therapeutic option should be effective and have a low cost. The first-line therapy of urinary tract infection (UTI) includes cephalosporin and fluoroquinolone.
Objective: To find out which antibiotic therapy is more cost-effective between ceftriaxone and levofloxacin using a cost-effectiveness analysis test.
Method: The study was conducted retrospectively using medical records and patient direct medical cost data for 2019 and 2020. The records of 21 patients met the inclusion criteria. Data processing and decision-making were carried out using descriptive and inferential statistical analysis, average cost-effectiveness (ACER) calculations, and a cost-effectiveness grid. The outcome parameter used in a cost-effectiveness analysis was the percentage of effectiveness of empirical therapy.
Result: The results showed that 61.9% of patients received ceftriaxone and 38.1% received levofloxacin. The average length of hospitalisation of UTI patients with levofloxacin therapy was shorter than those treated with ceftriaxone (four versus five days) with a p-value = 0.066. The average cost of ceftriaxone treatment was higher than that of levofloxacin (IDR 2,352,307 versus IDR 1,867,183). Based on statistical analysis carried out on each component of direct medical cost, the results were not significantly different between the cost of treatment with ceftriaxone or levofloxacin (p = 0.107). The percentage of effectiveness of empirical therapy using levofloxacin was higher than ceftriaxone (100% versus 90.5%). ACER value of total levofloxacin cost (IDR 18,672 per percentage effectiveness) has a lower value compared to ceftriaxone (IDR 26,000 per percentage effectiveness).
Conclusion: Using the cost-effectiveness grid, levofloxacin is a more effective therapy, therefore the treatment of UTIs at Soebandi public hospital using levofloxacin are more cost-effective.
References
Ananta, I. (2016). Penerapan pola pembayaran ina-cbgs bpjs kesehatan dalam tinjauan regulasi dan implementasi
Bader, M.S., Hawboldt, J., & Brooks, A. (2010). Management of Complicated Urinary Tract Infections in the Era of Antimicrobial Resistance. Postgraduate Medicine, 122(6), 7–15. https://doi.org/10.3810/pgm.2010.11.2217
Baek, H., Cho, M., Kim, S., Hwang, H., Song, M., & Yoo, S. (2018). Analysis of length of hospital stay using electronic health records: A statistical and data mining approach. PLOS ONE, 13(4). https://doi.org/10.1371/journal.pone.0195901
Baso, F.F., Perwitasari, D.A., & Risdiana, I. (2018). Efektivitas Antibiotik Golongan Sefalosporin Generasi Ke-3 Dibandingkan Fluroquinolon Terhadap Pasien Infeksi Saluran Kemih di RS PKU Muhammadiyah Yogyakarta. MPI (Media Pharmaceutica Indonesiana), 2(1), 26–34. https://doi.org/10.24123/mpi.v2i1.1300
Bientinesi, R., Murri, R., & Sacco, E. (2020). Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opinion on Pharmacotherapy, 21(6), 637–644. https://doi.org/10.1080/14656566.2020.1720647
Brusch, J.L. (2020). Urinary Tract Infection (UTI) in Males (online). Medscape. Available from: https://emedicine.medscape.com/article/231574-overview
EAU (European Association of Urology) (2022). EAU Guidelines on Urological Infections (online). Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2022.pdf
Hine, J. L., de Lusignan, S., Burleigh, D., Pathirannehelage, S., McGovern, A., Gatenby, P., Jones, S., Jiang, D., Williams, J., Elliot, A. J., Smith, G. E., Brownrigg, J., Hinchliffe, R., & Munro, N. (2017). Association between glycaemic control and common infections in people with Type 2 diabetes: A cohort study. Diabetic Medicine, 34(4), 551–557. https://doi.org/10.1111/dme.13205
Jafar, N., Edriss, H., & Nugent, K. (2016). The Effect of Short-Term Hyperglycemia on the Innate Immune System. The American Journal of the Medical Sciences, 351(2), 201–211. https://doi.org/10.1016/j.amjms.2015.11.011
Kang, C.-I., Kim, J., Park, D. W., Kim, B.-N., Ha, U.-S., Lee, S.-J., Yeo, J. K., Min, S. K., Lee, H., & Wie, S.-H. (2018). Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections. Infection & Chemotherapy, 50(1), 67. https://doi.org/10.3947/ic.2018.50.1.67
Podder, V. & Sadiq, N.M. (2022). Levofloxacin (online). Available from: https://www.ncbi.nlm.nih.gov/books/NBK545180/
Setiawan, D., Endarti, D. & Suwantika, A.A. (2017). Farmakoekonomi Modeling. UMP Press
Susono, R.F., & Galistiani, G.F. (2014). Cost Effectiveness Analysis of Cefotaxime and Chloramphenicol for Pediatric Inpatient with Typhoid Fever at Margono Soekarjo Hospital. Pharmacy, 11(1), 86-97. https://jurnalnasional.ump.ac.id/index.php/PHARMACY/article/view/854
Syahputra, R.R.I., Agustina, D., & Wahyudi, S.S. (2018). The Sensitivity Pattern of Bacteria Against Antibiotics in Urinary Tract Infection Patients at RSD DR. Soebandi Jember. Journal of Agromedicine and Medical Sciences, 4(3), 171. https://doi.org/10.19184/ams.v4i3.6786
Tri Murti Andayani. (2013). Farmakoekonomi: Prinsip dan Metodologi. Bursa Ilmu
Torayraju, K. (2015). Infeksi Saluran Kemih pada Geriatri. Multidisciplinary Journal of Science and Medical Research, 2(1). https://isainsmedis.id/index.php/ism/article/view/75
Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., & DiPiro, C.V. (2015). Pharmacotherapy handbook (Ninth edition). McGraw-Hill
